Tenaya Therapeutics, Inc. (TNYA) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Tenaya Therapeutics, Inc. (TNYA) closed at USD 0.39 on 2026-10-14, a change of -74.9 % over the past year, with a market capitalization of USD 91.58M.
Tenaya Therapeutics, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 0.39 |
| 2026-10-13 | 0.52 |
| 2026-10-12 | 0.57 |
| 2026-10-09 | 0.58 |
| 2026-10-08 | 0.54 |
| 2026-10-07 | 0.53 |
| 2026-10-06 | 0.55 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Tenaya Therapeutics, Inc. key figures
- Previous close
- USD 0.39 (2026-10-14)
- 1-year change
- -74.9 %
- Market cap
- USD 91.58M
- Enterprise value
- USD 17.44M
- P/E ratio (trailing)
- -1.05
- P/E ratio (forward)
- -1.04
- EPS (trailing)
- -0.39
- EPS (forward)
- -0.39
- PEG ratio
- n/a
- Price to book
- 1.32
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 9.61
- Employees
- 70
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Tenaya Therapeutics, Inc. and compare it with other stocks.
Analyze TNYAAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Tenaya Therapeutics, Inc. shares.